<DOC>
	<DOCNO>NCT00776711</DOCNO>
	<brief_summary>Study Design : This Phase I , randomize , open-label study evaluate safety , tolerability , immunogenicity four vaccination regimen influenza virus hemagglutinin H5 . One group receive A/Indonesia/05/2005 ( inactivate H5N1 ) vaccine prime boost , two group receive VRC-AVIDNA036-00-VP ( DNA ) vaccine prime inactivated H5N1 boost different boost interval , one group receive DNA vaccine twice prime follow H5N1 boost . The hypothesis regimens safe human administration elicit antibody T cell response H5 protein . The primary objective evaluate safety tolerability investigational vaccine regimen , dose 4 mg DNA vaccine 90 microgram inactivate H5N1 , healthy adult . Secondary exploratory objective relate immunogenicity study vaccine regimen . Product Description : The inactivated H5N1 vaccine monovalent subunit virion vaccine , A/Indonesia/05/2005 clade 2 , manufacture Sanofi Pasteur , Inc ( Swiftwater , PA ) . Vaccine vial supply 90 microgram/0.5mL . The VRC-AVIDNA036-00-VP vaccine develop manufactured VRC , NIAID compose single closed-circular DNA plasmid encodes H5 protein CMV/R promoter . Vaccine vial supply 4 mg/mL . Each vaccination administer intramuscularly ( IM ) deltoid muscle use needle syringe H5N1 vaccine Biojector ( Trademark ) 2000 Needle-Free Injection Management System ( Biojector ) DNA vaccine . Subjects : A total 60 healthy adult , age 18-60 year enrol . Study Plan : Subjects simultaneously randomize ratio 1:1:1:1 one four group . Subjects clinicians blind group assignment Day 0 follow completion enrollment . At point enrollment randomly assign regimen become known subject clinician . Subjects receive either two three injection schedule show schema . The protocol require five clinic visit two telephone follow-up contact Groups 1 , 2 , 3 , six clinic visit three telephone follow-up contact Group 4 .</brief_summary>
	<brief_title>Vaccine Prevention Bird Flu</brief_title>
	<detailed_description>Study Design : This Phase I , randomize , open-label study evaluate safety , tolerability , immunogenicity four vaccination regimen influenza virus hemagglutinin H5 . One group receive A/Indonesia/05/2005 ( inactivate H5N1 ) vaccine prime boost , two group receive VRC-AVIDNA036-00-VP ( DNA ) vaccine prime inactivated H5N1 boost different boost interval , one group receive DNA vaccine twice prime follow H5N1 boost . The hypothesis regimens safe human administration elicit antibody T cell response H5 protein . The primary objective evaluate safety tolerability investigational vaccine regimen , dose 4 mg DNA vaccine 90 microgram inactivate H5N1 , healthy adult . Secondary exploratory objective relate immunogenicity study vaccine regimen . Product Description : The inactivated H5N1 vaccine monovalent subunit virion vaccine , A/Indonesia/05/2005 clade 2 , manufacture Sanofi Pasteur , Inc ( Swiftwater , PA ) . Vaccine vial supply 90 microgram/0.5mL . The VRC-AVIDNA036-00-VP vaccine develop manufactured VRC , NIAID compose single closed-circular DNA plasmid encodes H5 protein CMV/R promoter . Vaccine vial supply 4 mg/mL . Each vaccination administer intramuscularly ( IM ) deltoid muscle use needle syringe H5N1 vaccine Biojector ( Trademark ) 2000 Needle-Free Injection Management System ( Biojector ) DNA vaccine . Subjects : A total 60 healthy adult , age 18-60 year enrol . Study Plan : Subjects simultaneously randomize ratio 1:1:1:1 one four group . Subjects clinicians blind group assignment Day 0 follow completion enrollment . At point enrollment randomly assign regimen become known subject clinician . Subjects receive either two three injection schedule show schema . The protocol require five clinic visit two telephone follow-up contact Groups 1 , 2 , 3 , six clinic visit three telephone follow-up contact Group 4 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : A subject must meet following criterion : 1 . 18 60 year old . 2 . Available clinical followup Week 48 . 3 . If enrol study opening ( November 2008 ) June 30 , 2009 , immunize current season FDAapproved influenza vaccine prior enrollment specify interval [ 14 day 24 week prior enrollment inactivated influenza vaccine OR 30 day 24 week prior enrollment liveattenuated influenza vaccine ( FluMist ( Registered Trademark ) ) ] ; subject enrol July 1 , 2009 require prior vaccination recent seasonal influenza vaccine . 4 . Able provide proof identity satisfaction study clinician complete enrollment process . 5 . Complete AoU prior enrollment verbalize understanding question answer incorrectly . 6 . Able willing complete inform consent process . 7 . Willing donate blood sample storage use future research . 8 . In good general health without clinically significant medical history . 9 . Physical examination laboratory result without clinically significant finding Body Mass Index ( BMI ) less 40 within 56 day prior enrollment . Laboratory Criteria within 56 day prior nrollment : 10 . Hemoglobin great equal 11.5 g/dL woman ; great equal 13.5 g/dL men 11 . White blood cell ( WBC ) = 3,30012,000 cells/mm ( 3 ) 12 . Differential either within institutional normal range accompany site physician approval 13 . Total lymphocyte count great equal 800 cells/mm ( 3 ) 14 . Platelets = 125,000 500,000/mm ( 3 ) 15 . Alanine aminotransferase ( ALT ) less 1.25 time upper limit normal ( ULN ) 16 . Serum creatinine less equal 1 time ULN ( less equal 1.3 mg/dL female ; le equal 1.4 mg/dL male ) 17 . Negative FDAapproved HIV blood test . [ Note : Results HIV enzymelinked immunosorbent assay ( ELISA ) document , negative HIV polymerase chain reaction ( PCR ) test result sufficient eligibility screen subject positive HIV ELISA due prior participation HIV vaccine study ] FemaleSpecific Criteria : 18 . Negative betaHCG pregnancy test ( urine serum ) woman presume reproductive potential . 19 . A female subject must meet one follow criterion : No reproductive potential menopause [ one year without menses ] hysterectomy , bilateral oophorectomy , tubal ligation , OR Agrees heterosexually inactive least 21 day prior enrollment Week 28 study , OR Agrees consistently practice contraception least 21 day prior enrollment Week 28 study one follow method : condom , male female , without spermicide ; diaphragm cervical cap spermicide ; intrauterine device ; contraceptive pill , patch , implant FDAapproved contraceptive method ; male partner previously undergone vasectomy . EXCLUSION CRITERIA : A subject exclude one follow condition apply . Women Specific : 1 . Breastfeeding plan become pregnant first 28 week enrollment study . Subject receive follow substance : 2 . Systemic immunosuppressive medication cytotoxic medication , within 12 week prior enrollment . [ With exception short course ( duration 10 day less single injection ) corticosteroid selflimited condition least 2 week prior enrollment study exclude study participation . ] 3 . Blood product within 112 day ( 16 week ) prior HIV screen 4 . Immunoglobulin within 56 day ( 8 week ) prior HIV screen 5 . Live attenuate vaccine within 28 day ( 4 week ) prior initial study vaccine administration 6 . Investigational research agent within 28 day ( 4 week ) prior initial study vaccine administration 7 . Medically indicated subunit kill vaccine , e.g . influenza , pneumococcal , allergy treatment antigen injection , within 14 day ( 2 week ) initial study vaccine administration 8 . Current antiTB prophylaxis therapy 9 . Previous H5 avian influenza investigational vaccine . Subject history follow clinically significant condition : 10 . Contraindication receive FDA approve current seasonal influenza vaccination ( e.g. , egg allergy ) 11 . Serious reaction vaccine preclude receipt study vaccination determine investigator . 12 . Hereditary angioedema ( HAE ) , acquire angioedema ( AAE ) , idiopathic form angioedema . 13 . Asthma unstable require emergent care , urgent care , hospitalization intubation past two year require use oral intravenous corticosteroid . 14 . Diabetes mellitus ( type I II ) , exception gestational diabetes . 15 . Thyroid disease well control . 16 . Idiopathic urticaria within past year . 17 . Hypertension well control medication 145/95 enrollment . 18 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draw . 19 . Malignancy active treat malignancy reasonable assurance sustain cure malignancy likely recur period study . 20 . Seizure disorder : 1 ) febrile seizures 2 ) seizure secondary alcohol withdrawal 3 year ago , 3 ) seizure require treatment within last 3 year . 21 . Asplenia , functional asplenia condition result absence removal spleen . 22 . Allergic reaction aminoglycoside antibiotic . 23 . GuillainBarr Syndrome . 24 . Psychiatric condition precludes compliance protocol ; past present psychosis ; past present bipolar disorder ; disorder require lithium ; within 5 year prior enrollment , history suicide plan attempt . 25 . Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 14, 2011</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Avian Influenza</keyword>
	<keyword>Immunity</keyword>
	<keyword>Preventive</keyword>
	<keyword>Bird Flu</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
	<keyword>Influenza</keyword>
</DOC>